char = 1;code = 49
1-Arylmethyl-2,3-dioxo-2,3-dihydroindole thiosemicarbazones as leads for developing cytotoxins and anticonvulsants.char = V;code = 86
Publication: J Enzyme Inhib Med Chem 2009 Apr ;24(2)::537-44. :doi: 10.1080/14756360802234885.
Publication Date: 2009 Apr
Study Author(s): Karki, Subhas S;Bahaduria, Vivek Singh;Rana, Vivek;Kumar, Sujeet;Subbaro, Prasanna G;Das, Umashankar;Balzarini, Jan;De Clercq, Erik;Dimmock, Jonathan R;
Institution: Department of Pharmaceutical Chemistry, India.
[email protected]
Shortcut link to this study:
Various substituted 1-arylmethyl-2,3-dioxo-2,3-dihydroindole thiosemicarbazones 3a-h, 1-benzyl-2,3-dioxo-2,3-dihydroindole N(4)-aryl thiosemicarbazones 4a-i and 1-benzyl-2,3-dioxy-2,3-dihydroindole N(4)-cyclohexylthiocarbazone 5 were synthesized. All of these compounds were evaluated against human Molt 4/C8 and CEM T-lymphocytes as well as murine L1210 leukemia cells. Nearly 40% of these compounds possess low micromolar IC(50) values and some are either more potent than, or equipotent with, melphalan. Various correlations between the structures of these compounds and cytotoxic potencies were obtained which included the use of QSAR and molecular modeling techniques. Representative compounds displayed anticonvulsant properties in rats and were well tolerated by these animals. The encouraging biodata noted affords adequate rationale for outlining guidelines for further development of these molecular scaffolds.
PMID: 18608748
How is this determined?
